Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2019-03-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2019-03-06 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and board resolution details. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the 'RNS' category as it does not fit into specific categories like 'DIRS' (which is for director dealings) or 'SHA' (which is for share issuance/capital changes).
2019-03-05 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company '아이진'. It outlines the date, location, and the agenda items (proposals) to be voted on, such as financial statement approval, director appointments, and remuneration limits. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of upcoming voting items.
2019-03-05 Korean
투자판단관련주요경영사항(심근허혈 및 재관류 손상 치료제 ‘이지-마이오신 (EG-Myocin)’ 임상2상 시험 계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 2 clinical trial for a drug candidate. Since this is a specific regulatory announcement regarding company operations and clinical trial status that does not fit into financial reporting or shareholder meeting categories, it is classified as a general regulatory filing.
2019-02-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) announcing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting material financial changes before the final audit is completed. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and the reasons for the variance, rather than being a full annual report or a simple announcement of a report's publication. FY 2018
2019-02-13 Korean
신규시설투자등
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene context) announcing a 'New Facility Investment' (신규시설투자). It details the investment amount, purpose (GMP facility construction), and board resolution date. This type of disclosure regarding capital expenditure and facility investment falls under general regulatory announcements as it does not fit into specific categories like M&A, share issuance, or financial reports.
2019-02-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.